171 related articles for article (PubMed ID: 35529783)
41. Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases.
Kowalski ES; Remick JS; Sun K; Alexander GS; Khairnar R; Morse E; Cherng HR; Berg LJ; Poirier Y; Lamichhane N; Becker S; Chen S; Molitoris JK; Kwok Y; Regine WF; Mishra MV
Radiat Oncol; 2020 Oct; 15(1):245. PubMed ID: 33109224
[TBL] [Abstract][Full Text] [Related]
42. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
43. The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review.
Brahm CG; van Linde ME; Enting RH; Schuur M; Otten RHJ; Heymans MW; Verheul HMW; Walenkamp AME
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32143288
[TBL] [Abstract][Full Text] [Related]
44. An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer.
Zhang S; Yang L; Yang Y; Xin Y; Wang Y
Thorac Cancer; 2022 Dec; 13(23):3374-3383. PubMed ID: 36274215
[TBL] [Abstract][Full Text] [Related]
45. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC.
Mao S; Zhou F; Liu Y; Yang S; Chen B; Xu J; Wu F; Li X; Zhao C; Wang W; Liu Q; Yu X; Jia K; Shao C; Zhou C; Gao G; Ren S
Cancer Immunol Immunother; 2022 Jan; 71(1):219-228. PubMed ID: 34097116
[TBL] [Abstract][Full Text] [Related]
46. Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma.
Xiao G; Li L; Tanzhu G; Liu Z; Gao X; Wan X; Xiao D; Chen L; Xia X; Zhou R
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36868569
[TBL] [Abstract][Full Text] [Related]
47. Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study.
Li X; Lu D; Zhang Z; Zhang Y; Wang J; Hu Y
J Thorac Dis; 2022 Oct; 14(10):4125-4135. PubMed ID: 36389301
[TBL] [Abstract][Full Text] [Related]
48. Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis.
Qiu L; Gao S; Du S; Sun S; Liang Y; Sun Z; Li T; Jia G; Li K; Sun X; Jiao S; Zhao X
Front Oncol; 2022; 12():974227. PubMed ID: 36523994
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Zhong Q; Liu Z
Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
[TBL] [Abstract][Full Text] [Related]
50. Intracranial radiotherapy with or without immune checkpoint inhibition for brain metastases: a systematic review and meta-analysis.
He Q; Zhang C; Tang S; Li J; Ren Q
Transl Cancer Res; 2020 Oct; 9(10):5909-5924. PubMed ID: 35117204
[TBL] [Abstract][Full Text] [Related]
51. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; Master VA; El-Rayes BF; Ramalingam SS; Owonikoko TK; Harvey RD; Bilen MA
Invest New Drugs; 2019 Dec; 37(6):1198-1206. PubMed ID: 30725388
[TBL] [Abstract][Full Text] [Related]
52. Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis.
Kang S; Jeong H; Park JE; Kim HS; Kim YH; Lee DH; Kim SW; Lee JC; Choi CM; Yoon S
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4523-4532. PubMed ID: 36136277
[TBL] [Abstract][Full Text] [Related]
53. Identification of prognostic biomarkers for breast cancer brain metastases based on the bioinformatics analysis.
Wu Z; Wan J; Wang J; Meng X; Qian H
Biochem Biophys Rep; 2022 Mar; 29():101203. PubMed ID: 35059509
[TBL] [Abstract][Full Text] [Related]
54. Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups.
Trommer M; Adams A; Celik E; Fan J; Funken D; Herter JM; Linde P; Morgenthaler J; Wegen S; Mauch C; Franklin C; Galldiks N; Werner JM; Kocher M; Rueß D; Ruge M; Meißner AK; Baues C; Marnitz S
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267546
[TBL] [Abstract][Full Text] [Related]
55. Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study.
Qiang H; Lei Y; Shen Y; Li J; Zhong H; Zhong R; Zhang X; Chang Q; Lu J; Feng H; Zhu Y; Addeo A; Banna GL; Oh IJ; Qian J; Chu T
Transl Lung Cancer Res; 2022 Jan; 11(1):87-99. PubMed ID: 35242630
[TBL] [Abstract][Full Text] [Related]
56. Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer.
Minami S; Ihara S; Tanaka T; Komuta K
World J Oncol; 2020 Feb; 11(1):9-22. PubMed ID: 32095185
[TBL] [Abstract][Full Text] [Related]
57. Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis.
Chen H; Feng Y; Zhou Y; Tao Y; Tang L; Shi Y
Cancer Immunol Immunother; 2022 Dec; 71(12):3071-3085. PubMed ID: 35648238
[TBL] [Abstract][Full Text] [Related]
58. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
59. Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer.
Li C; Shi M; Lin X; Zhang Y; Yu S; Zhou C; Yang N; Zhang J; Zhang F; Lv T; Liu H; Song Y
Transl Lung Cancer Res; 2021 Feb; 10(2):776-789. PubMed ID: 33718021
[TBL] [Abstract][Full Text] [Related]
60. Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases.
Koenig JL; Shi S; Sborov K; Gensheimer MF; Li G; Nagpal S; Chang SD; Gibbs IC; Soltys SG; Pollom EL
World Neurosurg; 2019 Jun; 126():e1399-e1411. PubMed ID: 30902777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
